Lesson
Diagnose Disease and Measure the Whole Burden
Atopic dermatitis is a relapsing pruritic inflammatory disease diagnosed clinically. Morphology, age-patterned distribution, xerosis, chronicity, burden, and competing diagnoses matter together.
- Pruritic eczema
- Age distribution
- Validated severity
- Mimics
- Urgent infection
Use age, site, morphology, xerosis, and history
Measure itch, sleep, pain, infection, function, and mood
Consider contact disease, scabies, psoriasis, infection, and drug eruption
Escalate infection and systemic threat
Build the clinical pattern
Ask when itch began, where rash appears, how it changes, and whether xerosis, flexural disease, facial or hand involvement, lichenification, family atopy, asthma, or rhinitis supports the pattern. Infants often have cheek, trunk and extensor involvement; flexural disease becomes more typical in childhood, with hand and foot disease prominent in adolescents and young adults. These are patterns, not diagnostic requirements. Skin color changes how erythema appears.
Measure more than surface area
Use a consistent clinician measure such as EASI or a validated global assessment when available, plus body surface area, itch, sleep, pain, infections, school or work, mood, and treatment burden. Hands, face, eyelids, and genitals can cause major disability with limited area.
Protect the differential
Allergic or irritant contact dermatitis, scabies, psoriasis, seborrheic dermatitis, dermatophyte infection, drug eruption, immunodeficiency, cutaneous lymphoma, and other disorders can mimic eczema. Unusual age, morphology, distribution, systemic findings, or treatment failure requires reassessment.
Escalate dangerous change
Fever, severe pain, rapidly spreading redness, purulence, eye symptoms, or clusters of painful vesicles and punched-out erosions can indicate serious bacterial infection or eczema herpeticum. These findings need prompt direct evaluation.
Quick check
Checking for saved practice…
Lesson
Connect Barrier Failure, Immunity, and Itch
Barrier proteins and lipids, type 2 inflammation, microbial interaction, neural itch, and scratching form a self-reinforcing circuit. Treatment must interrupt several links.
- Barrier lipids
- IL-4 and IL-13
- IL-31
- JAK signaling
- Itch scratch cycle
Dryness and fissures increase irritant entry
Inflammation and itch weaken the barrier
Excoriation deepens inflammation and infection risk
Treat both sides of the circuit
Start with the barrier
Impaired proteins and lipids increase transepidermal water loss and allow irritants, allergens, and microbes to interact with the immune system. Moisturizer supports barrier function but does not replace anti-inflammatory treatment during active disease.
Map type 2 signaling
IL-4 and IL-13 contribute to inflammation and further barrier dysfunction. IL-31 is strongly linked to itch, while intracellular JAK pathways transmit several cytokine signals. These pathways explain targeted therapies without reducing the disease to one molecule.
Break the itch scratch circuit
Scratching injures skin, intensifies inflammation, increases infection risk, and disrupts sleep. Control skin inflammation, protect nails and sleep, reduce friction, and use behavioral and physical strategies.
Do not confuse sedation with disease control
Oral antihistamines do not routinely treat the core inflammation or itch of atopic dermatitis. A short sedating strategy may occasionally address severe sleep disruption under clinician direction, but it adds cognitive, anticholinergic, respiratory, and fall risks. A nonsedating antihistamine may still have a separate role for coexisting allergic rhinitis or dermatographism; that does not make it a substitute for eczema treatment.
Quick check
Checking for saved practice…
Lesson
Engineer Daily Barrier Care and Trigger Reasoning
Bathing, moisturizer, cleanser, climate, sensory preference, work, and reproducible exposures shape the barrier. Broad avoidance and unvalidated food restriction can create harm.
- Bathing
- Moisturizer vehicle
- Fragrance and cleanser
- Contact allergy
- Food restriction
Avoid prolonged hot exposure
Choose a tolerated ointment, cream, or lotion
Reduce cleanser and product burden
Use patch testing when contact allergy is plausible
Add water, then retain it
Use brief comfortable bathing and a gentle cleanser only where needed. Pat rather than rub and apply a generous fragrance-free moisturizer promptly while skin is still slightly damp. Frequency and vehicle should match the patient and climate.
Select a usable vehicle
Ointments are highly occlusive, creams balance occlusion and feel, and lotions are lighter but often less occlusive and may contain more water or preservatives. The best product is bland, affordable, tolerated, and used consistently.
Find irritants and contact allergy
Review fragrance, preservatives, soaps, metals, adhesives, gloves, wet work, hair and cosmetic products, occupation, heat, sweat, friction, and clothing. Patch testing can identify allergic contact dermatitis when site, exposure, or treatment resistance supports it.
Avoid unsupported restriction
Food allergy can coexist, especially in children, but broad panels and elimination diets do not diagnose the cause of eczema. Restriction without a convincing immediate history and specialist evaluation can impair nutrition, growth, and quality of life.
Quick check
Checking for saved practice…
Lesson
Use Topical Corticosteroids with Measured Precision
Topical corticosteroids remain foundational. Potency, vehicle, site, age, amount, frequency, duration, occlusion, and total steroid exposure determine benefit and harm.
- Potency classes
- Fingertip units
- Sensitive sites
- Wet wraps
- Cumulative toxicity
Skin vulnerability and thickness differ
Write grams, frequency, duration, and stop rules
Avoid undertreatment driven by vague fear
Watch atrophy, striae, eye, infection, growth, and HPA risk
Match potency to anatomy and flare
Thick hand, foot, or lichenified disease may require greater potency than face, eyelid, fold, or genital skin. Children and large-area disease increase absorption. US potency classes run from I, the strongest, to VII, the weakest. Potency belongs to the exact formulation: for example, mometasone 0.1 percent ointment is more potent than its cream. Do not rank all products by concentration or assume a universal ointment-to-spray hierarchy. Frequency and duration also follow the exact product and treatment plan; neither once daily for all high-potency products nor a universal two-week stop rule is sufficient.
Make the dose measurable
One adult fingertip unit is a strip from the distal index-finger crease to the tip through a standard 5 mm nozzle, approximately 0.5 gram. It covers roughly two adult handprints, including fingers; this is an estimate, not a universal dose for every body site or age. For a prescribed area requiring 2 fingertip units per application, twice daily for 7 days, the course estimate is 2 × 0.5 × 2 × 7 = 14 grams. Compare actual use with the prescribed area, schedule and product limits. Demonstrate the amount, and specify the step-down plan.
Counsel without amplifying phobia
Explain that adequate short-course treatment prevents prolonged inflammation, while unsupervised high-potency or continuous sensitive-site use can cause atrophy, striae, telangiectasia, acneiform change, periorificial dermatitis, ocular harm, and systemic absorption.
Treat occlusion as a dose multiplier
Wet wraps can rapidly improve selected flares, but hydration and occlusion increase drug delivery. Use clinician-directed potency, dilution when applicable, area, duration, temperature, infection screening, and caregiver technique.
Quick check
Checking for saved practice…
Lesson
Use Established Steroid-Sparing Topicals
Topical calcineurin inhibitors and crisaborole reduce inflammation without corticosteroid atrophy. Their distinct mechanisms, labels, sensations, and maintenance roles guide use.
- Tacrolimus
- Pimecrolimus
- Crisaborole
- Application burning
- Proactive therapy
Calcineurin inhibitors avoid steroid atrophy
Set expectations and protect adherence
Start twice daily; consider once daily after clinical effect
Treat recurrent sites between flares
Use calcineurin inhibitors on vulnerable sites
Tacrolimus ointment and pimecrolimus cream are useful on the face, eyelids, folds, and other sites where corticosteroid atrophy is concerning. US labeling uses these as second-line, short-term or noncontinuous chronic therapy in non-immunocompromised patients when other prescription topicals are inadequate or inadvisable. Tacrolimus treats moderate to severe disease: ages 2 through 15 use only 0.03 percent ointment; from age 16, either 0.03 or 0.1 percent may be used. Pimecrolimus 1 percent cream treats mild to moderate disease from age 2. Both are applied twice daily to affected skin and stopped when signs and symptoms resolve. Reassess persistent or unimproved disease at 6 weeks rather than continuing automatically. Avoid occlusive dressings and eye or mucosal exposure.
Discuss the warning accurately
Transient burning or stinging is common, especially on inflamed skin. The boxed warnings describe rare reported malignancies and uncertain long-term safety; they do not establish that topical treatment causes cancer. Avoid continuous long-term use, resolve infection at treatment sites first, and minimize ultraviolet exposure. Suspicious lesions or a treatment-resistant eruption need reassessment rather than escalating immunosuppression over a possible malignancy.
Account for systemic exposure and reproduction
Systemic interactions are less likely with topical calcineurin inhibitors, but cannot be excluded. Review CYP3A inhibitors particularly with widespread or erythrodermic disease. Both labels lack adequate controlled human pregnancy studies; assess maternal benefit and potential fetal risk rather than assigning safety from the topical route. Their US nursing instructions call for a shared decision about continuing treatment or breastfeeding, considering the medicine’s importance to the mother. Avoid direct infant contact with treated skin.
Place crisaborole precisely
Crisaborole 2 percent ointment is labeled for mild to moderate disease from age 3 months. Apply a thin layer twice daily initially; once clinical effect is achieved, consider reducing application to once daily. Application-site pain or burning can limit use, and rare hypersensitivity requires discontinuation and evaluation.
Maintain recurrent sites proactively
For frequent recurrence at the same sites, guidelines support clinician-directed intermittent anti-inflammatory treatment after flare control, alongside daily moisturizer. Twice-weekly tacrolimus is one studied proactive approach. Explain that this guideline-supported maintenance plan differs from the US flare-label instruction to stop when symptoms resolve; it is not permission for continuous daily use. Choose the drug and schedule for age, site and prior response, and track rescue days and adverse effects.
Quick check
Checking for saved practice…
Lesson
Navigate the Current Nonsteroidal Topical Landscape
The 2025 AAD focused update strongly recommends tapinarof and roflumilast for adult disease, while current labels add pediatric, strength, area, and exposure details. Current labeling includes topical ruxolitinib for eligible patients from age two.
- Tapinarof
- Roflumilast
- Ruxolitinib
- Age-specific strengths
- Body surface limits
Once daily from age 2
Age-specific 0.05 and 0.15 percent strengths
Short-term, noncontinuous, up to 20 percent body area
Topical route still requires exposure controls
Use tapinarof by indication
Tapinarof cream 1 percent is an aryl hydrocarbon receptor agonist labeled once daily for atopic dermatitis in adults and children age 2 and older. Folliculitis, respiratory infections and headache occur in the atopic dermatitis trial safety profile; contact dermatitis is also reported in the psoriasis program. Check new rash or intolerance rather than assuming every change is eczema. Wash hands after applying unless treating the hands; avoid eyes, mouth and vaginal use.
Use the correct roflumilast strength
Roflumilast is a PDE4 inhibitor. Current labeling uses cream 0.15 percent once daily from age 6 and cream 0.05 percent once daily from age 2 through 5 for mild to moderate atopic dermatitis. Do not use with Child-Pugh B or C liver impairment. Systemic CYP3A4 inhibitors, combined CYP3A4/CYP1A2 inhibitors, and gestodene/ethinyl estradiol can increase exposure; weigh benefit against added adverse effects. Monitor headache, gastrointestinal symptoms and application pain. Avoid use during labor and delivery; during breastfeeding minimize area and duration and prevent infant contact, including nipple or areolar application.
Respect topical ruxolitinib limits
Ruxolitinib 1.5 percent cream is for non-immunocompromised patients from age 2 with mild to moderate disease when prescription topicals are inadequate or inadvisable. Apply twice daily over at most 20 percent body surface area without occlusion. Ages 2 through 11 must not exceed 60 grams per 2 weeks; from age 12, the limit is 60 grams per week or 100 grams per 2 weeks. Stop when symptoms resolve; reassess if unimproved at 8 weeks. These are exposure ceilings, not target amounts.
Keep boxed safety visible
The boxed warning addresses serious infection, mortality, malignancy, major cardiovascular events and thrombosis; cytopenias are an additional precaution. Some risk evidence comes from oral JAK treatment in higher-risk rheumatoid arthritis populations, so do not equate event rates across routes and diseases. Avoid strong CYP3A4 inhibitors; combining with therapeutic biologics, other JAK inhibitors or potent immunosuppressants is not recommended. Avoid breastfeeding during treatment and for approximately 4 weeks afterward.
Quick check
Checking for saved practice…
Lesson
Separate Flare Rescue from Infection Treatment
Inflamed eczema is not automatically infected. Bacterial infection, eczema herpeticum, fungal disease, and irritant reactions require different actions, while wraps and bleach baths require exact technique.
- Impetiginization
- Eczema herpeticum
- Antimicrobial stewardship
- Wet wraps
- Bleach baths
Identify bacterial, viral, fungal, or systemic threat
Avoid routine antimicrobials for every flare
Occlusion changes absorption and infection risk
Exact volume, concentration, frequency, and supervision
Find clinical infection
Pain, purulence, pustules, rapidly spreading erythema, fever, systemic illness, or worsening despite adequate anti-inflammatory care supports bacterial evaluation. Culture severe, recurrent, unusual, or treatment-resistant disease when results will change care.
Protect the herpes pathway
Painful monomorphic vesicles, punched-out erosions, fever, malaise, or eye-area involvement raises concern for eczema herpeticum. Arrange prompt antiviral and ophthalmic evaluation when relevant rather than waiting for routine flare treatment.
Avoid routine antimicrobials
AAD guidance recommends against routine topical antimicrobials and antiseptics for uninfected dermatitis. Oral antibiotics are reserved for evidence of bacterial infection and are combined with adequate eczema therapy.
Measure physical adjuncts
Wet wraps require product and duration supervision. Dilute bleach baths are an optional adjunct for selected moderate to severe disease; prior infection is not an absolute prerequisite, and they do not replace anti-inflammatory care. A studied final sodium hypochlorite concentration is approximately 0.005 percent, often for 10 minutes twice weekly. The clinician must match the recipe to measured water volume and product concentration; avoid scented or splashless additives, mix before entering, and never apply undiluted bleach. Never mix bleach with ammonia products or use the bath immediately after cleaning it with an ammonia-based cleaner. Avoid with uncontrolled asthma or bleach contact allergy. Ventilate, keep the head out of the bath, rinse afterward and resume prescribed skin care. Stop for airway or eye irritation and reassess if there is no benefit after 4 weeks.
Quick check
Checking for saved practice…
Lesson
Select Phototherapy and Biologics by Pathway and Product
Current systemic guidance strongly supports dupilumab, tralokinumab, lebrikizumab, and nemolizumab for appropriate disease. Target, age, weight, topical companion use, eye risk, vaccination, and schedule differ.
- Narrowband UVB
- Dupilumab
- Tralokinumab
- Lebrikizumab
- Nemolizumab
Broad type 2 pathway with product-specific age and weight dosing
Distinct labels, schedules, and eye monitoring
Itch pathway with concomitant topical therapy
Dosed medical exposure, not tanning
Use phototherapy as measured medicine
Narrowband UVB can treat selected widespread disease when topical care is inadequate and attendance is feasible. Review skin cancer, photodermatosis, photosensitizing medicines, burns, pigment response, eye protection, pregnancy, and cumulative exposure. Tanning beds are not equivalent.
Differentiate type 2 biologics
Dupilumab blocks IL-4 receptor alpha signaling, while tralokinumab and lebrikizumab target IL-13. The separate dupilumab lesson provides its age-weight regimen. Tralokinumab treats moderate to severe disease from age 12 after inadequate or inadvisable prescription topicals. Adults receive 600 mg subcutaneously initially, then 300 mg every 2 weeks; ages 12-17 receive 300 mg initially, then 150 mg every 2 weeks using prefilled syringes. The autoinjector is for adults. Adults below 100 kg with clear or almost clear skin after 16 weeks may consider 300 mg every 4 weeks; that exception is not the adolescent regimen.
Place lebrikizumab accurately
Lebrikizumab treats moderate to severe disease from age 12 at a weight of at least 40 kg when prescription topicals are inadequate or inadvisable. Give 500 mg subcutaneously at weeks 0 and 2, then 250 mg every 2 weeks until week 16 or later, when response is adequate. The June 2026 label allows maintenance of 250 mg every 4 weeks or every 8 weeks. Do not shorten induction merely because the maintenance options are less frequent.
Plan biologic safety follow-up
Dupilumab, tralokinumab and lebrikizumab require prompt reporting of new or worsening eye symptoms. For tralokinumab and lebrikizumab, treat pre-existing helminth infection first and discontinue if an infection acquired during treatment fails antihelminth therapy, until it resolves. Avoid live vaccines during treatment under current labels and complete appropriate vaccines beforehand. Do not abruptly withdraw corticosteroids when initiating dupilumab; coordinate any reduction. Review hypersensitivity and new symptoms rather than assuming a targeted drug has no systemic effects.
Place nemolizumab accurately
Nemolizumab blocks IL-31 receptor alpha and is labeled with topical corticosteroids and or calcineurin inhibitors for selected moderate to severe disease from age 12. For atopic dermatitis, give 60 mg subcutaneously initially as two 30 mg injections, then 30 mg every 4 weeks. After 16 weeks, patients with clear or almost clear skin should receive 30 mg every 8 weeks. This atopic dermatitis schedule is not weight-based; do not import the weight-based maintenance regimen for adult prurigo nodularis. Use with topical corticosteroids and/or calcineurin inhibitors when prescription topical treatment has been inadequate; discontinue those companion topicals once disease has sufficiently improved, as directed by the label.
Quick check
Checking for saved practice…
Lesson
Choose the Dupilumab Regimen by Age and Weight
The atopic dermatitis regimen depends on both age and weight. Identify the indication before interpreting an injection schedule.
- Age bands
- Weight bands
- Loading dose
- Injection interval
- Missed dose
Check the indication before the regimen
Use the matching band in the lesson
Loading differs between age groups
Document injection dates and missed-dose instructions
Start with the indication
Dupilumab is an IL-4 receptor alpha antagonist for moderate to severe atopic dermatitis from age 6 months when prescription topical treatment is inadequate or inadvisable. Topical corticosteroids may accompany treatment.
Adult regimen
Give 600 mg subcutaneously initially, then 300 mg every 2 weeks.
Ages 6 months through 5 years
There is no loading dose. For 5 to less than 15 kg, give 200 mg every 4 weeks; for 15 to less than 30 kg, give 300 mg every 4 weeks. Do not extrapolate beyond listed weight bands.
Ages 6 through 17 years
For 15 to less than 30 kg: 600 mg initially, then 300 mg every 4 weeks. For 30 to less than 60 kg: 400 mg initially, then 200 mg every 2 weeks. For at least 60 kg: 600 mg initially, then 300 mg every 2 weeks.
Recover a missed injection
For either the every-2-week or every-4-week regimen, administer within 7 days and retain the original schedule. If later, administer and establish a new schedule from that date.
Keep counseling attached to the prescription
Review vaccination, eye symptoms and steroid transition with the prescriber. Follow the product instructions for the selected injection device.
Quick check
Checking for saved practice…
Lesson
Prescribe Abrocitinib Through Its Safety Gates
Abrocitinib requires a distinct platelet, interaction and renal assessment. A generic JAK checklist cannot replace the product-specific decision.
- Prior systemic therapy
- Platelet threshold
- Renal function
- CYP2C19
- Monitoring
Also check ALC, ANC and hemoglobin
Renal function and CYP2C19 may require 50 mg
Repeat 4 weeks after dose escalation
Specific restrictions apply during the first 3 months
Confirm the treatment position
Abrocitinib is labeled from age 12 for refractory moderate to severe atopic dermatitis after inadequate control with other systemic drugs, including biologics, or when those therapies are inadvisable. Combining it with other JAK inhibitors, biologic immunomodulators or other immunosuppressants is not recommended.
Select the initial and escalation doses
The usual starting dose is 100 mg orally once daily. If response is inadequate, consider 200 mg once daily; discontinue for inadequate response at 200 mg. Maintain response with the lowest effective dose. Swallow tablets whole; do not split, crush or chew.
Adjust for kidney function and metabolism
For eGFR 30-59 mL/min, start 50 mg daily and consider 100 mg if needed. Use is not recommended below 30 mL/min, including end-stage renal disease. CYP2C19 poor metabolizers and patients taking strong CYP2C19 inhibitors also start at 50 mg, may increase to 100 mg, and should discontinue if that is ineffective. Severe hepatic impairment, Child-Pugh C, is another setting where use is not recommended.
Distinguish initiation from interruption
Do not initiate with platelets below 150,000/mm3, ALC below 500/mm3, ANC below 1,000/mm3 or hemoglobin below 8 g/dL. During treatment, platelets below 50,000/mm3 require discontinuation and CBC follow-up until above 100,000/mm3; that follow-up target is not an automatic restart instruction. ALC below 500, ANC below 1,000 or hemoglobin below 8 requires temporary discontinuation until the relevant value recovers above its threshold.
Check antiplatelets and metabolic interactions
Antiplatelet therapy is contraindicated during the first 3 months except aspirin at no more than 81 mg daily. Do not stop cardiovascular protection merely to enable eczema treatment; coordinate an alternative plan. Avoid moderate-to-strong inhibitors of both CYP2C19 and CYP2C9 and moderate or strong inducers of either enzyme. Abrocitinib can also raise concentrations of certain P-gp and CYP2C19 substrates. Review drugs for which small concentration increases can cause serious toxicity, and arrange monitoring or dose changes using the affected drug’s label.
Schedule surveillance
Obtain baseline CBC, repeat at 4 weeks after starting and 4 weeks after each dose increase. Assess lipids around week 4. Screen for tuberculosis and viral hepatitis, review serious infection risk, and counsel about thrombosis and cardiovascular symptoms. Avoid live vaccines immediately before, during and immediately after treatment; complete indicated vaccination beforehand. Consider closer glucose monitoring in diabetes because hypoglycemia has been reported after JAK initiation.
Plan missed doses and reproductive counseling
Take a missed dose when remembered unless the next dose is less than 12 hours away; then skip it. Avoid breastfeeding during treatment and for one day after the last dose. Discuss pregnancy and fertility before treatment: human pregnancy data are insufficient to establish risk, and animal studies report developmental effects and possible female fertility impairment. Do not interpret limited human data as evidence of safety.
Quick check
Checking for saved practice…
Lesson
Match Upadacitinib Dose and Monitoring to Atopic Dermatitis
Upadacitinib dosing differs by indication. For atopic dermatitis, age, weight, renal function and CYP3A4 inhibitors determine whether escalation is appropriate.
- Age and weight
- Extended-release tablets
- Renal dose
- CYP3A4
- Reproductive safety
Pediatric weight must be at least 40 kg
Escalation depends on response and dose limits
Lipid assessment is around week 12
Contraception during treatment and for 4 weeks afterward; no breastfeeding during treatment or for 6 days afterward
Confirm eligibility
US labeling covers refractory moderate to severe disease from age 12 after other systemic drugs, including biologics, have been inadequate or inadvisable. Pediatric atopic dermatitis dosing requires weight of at least 40 kg. Use the extended-release tablet; the oral solution is not an interchangeable substitute and its pediatric atopic dermatitis use has not been established.
Start and escalate deliberately
For eligible patients under 65, start 15 mg orally daily and consider 30 mg daily if response is inadequate. Discontinue if 30 mg is ineffective and otherwise use the lowest effective dose. Adults 65 and older receive 15 mg daily. Do not use the 45 mg inflammatory bowel disease induction regimen for eczema.
Apply renal, hepatic and interaction limits
For eGFR 15 to less than 30 mL/min/1.73 m2, use 15 mg daily; use is not recommended below 15. No renal adjustment is needed at eGFR 30 or higher. With strong CYP3A4 inhibitors, the atopic dermatitis dose is 15 mg daily; avoid grapefruit and do not combine with strong CYP3A4 inducers. Severe hepatic impairment, Child-Pugh C, is not recommended.
Monitor counts and liver tests
Do not initiate or continue through ALC below 500/mm3, ANC below 1,000/mm3 or hemoglobin below 8 g/dL. Interrupt until counts recover above the relevant threshold. Check liver enzymes before and during treatment; interrupt suspected drug-induced liver injury until it is excluded. Assess lipids at approximately 12 weeks, rather than importing the four-week abrocitinib schedule.
Protect against infection and combined immunosuppression
Screen for tuberculosis and hepatitis, update indicated vaccines and avoid live vaccination immediately before or during therapy. Interrupt a serious infection until controlled. Combining with other JAK inhibitors, biologic immunomodulators or other immunosuppressants is not recommended. The shared systemic-safety lesson addresses malignancy, cardiovascular and thrombosis selection.
Use a specific reproductive plan
Verify pregnancy status before treatment because animal studies indicate fetal harm. Use effective contraception during treatment and for 4 weeks after the last dose. Breastfeeding is not recommended during use or for 6 days afterward. Swallow tablets whole rather than crushing, chewing or splitting them.
Quick check
Checking for saved practice…
Lesson
Use Systemic Therapy with a Durable Safety Strategy
Oral JAK inhibitors offer rapid targeted therapy for selected patients, conventional immunosuppressants remain conditional options, and routine systemic corticosteroids are discouraged because rescue without durability can rebound.
- Abrocitinib
- Upadacitinib
- Cyclosporine
- Methotrexate
- Systemic corticosteroids
Screen infection, thrombosis, cardiovascular, cancer, and laboratory risk
Cyclosporine, methotrexate, azathioprine, or mycophenolate
Rebound and cumulative harm undermine durable care
Every rescue needs a long-term plan
Screen oral JAK candidates
Abrocitinib and upadacitinib require current-label assessment of serious infection, tuberculosis, viral hepatitis, malignancy, major cardiovascular events, thrombosis, blood counts, liver, lipids, vaccination, pregnancy, smoking, age, and CYP interactions.
Use conventional agents deliberately
These are off-label US options for atopic dermatitis. AAD conditionally recommends cyclosporine, methotrexate, azathioprine and mycophenolate with appropriate monitoring. The 2023 allergy Joint Task Force instead conditionally suggests against azathioprine, methotrexate and mycophenolate in its refractory-disease pathway. The recommendations reflect different benefit-risk judgments and treatment contexts; they do not make these drugs interchangeable or preferred over every approved alternative. Document the guideline, prior treatment, patient goals and reason for selection.
Cyclosporine: protect kidney function and pressure
Monitor blood pressure, creatinine and electrolytes, including potassium, and review interacting medicines. Neoral modified and Sandimmune nonmodified formulations are not bioequivalent; switching requires prescriber supervision and additional monitoring. Select a limited treatment course and transition plan rather than assuming indefinite maintenance.
Methotrexate: protect the weekly schedule
Use a clearly written specialist regimen with a named weekly dosing day and prescribed folate supplementation. Accidental daily administration of a weekly dose has caused deaths. Monitor marrow, liver and kidney function and assess new pulmonary symptoms. Methotrexate is contraindicated during pregnancy for nonmalignant disease; establish the product-specific reproductive plan before treatment.
Azathioprine: connect metabolism to marrow safety
TPMT and NUDT15 deficiency can markedly increase myelotoxicity. Incorporate appropriate enzyme or genetic assessment into the specialist plan, but never replace serial CBC monitoring with a normal test result. Allopurinol requires a major azathioprine dose reduction under supervision; concomitant febuxostat is not recommended. Review liver function, infection and malignancy risk as well.
Mycophenolate: plan pregnancy prevention and count monitoring
Mycophenolate increases risks of pregnancy loss and congenital malformations. Select an alternative when pregnancy is planned whenever possible. Its label requires pregnancy testing immediately before initiation, again 8-10 days later and during routine follow-up, with acceptable contraception during treatment and for 6 weeks afterward for females of reproductive potential. Oral contraceptive pills alone may be insufficient under its labeled contraceptive options. Monitor blood counts and promptly evaluate infection, unexplained bruising or bleeding; gastrointestinal toxicity can also limit treatment.
Avoid routine systemic corticosteroids
AAD guidelines recommend against systemic corticosteroids for routine atopic dermatitis management. Short-lived improvement can be followed by rebound, while repeated exposure adds infection, metabolic, bone, eye, mood, adrenal, and cardiovascular harm.
Design the transition before rescue
Every systemic plan needs response targets, timing, laboratory and symptom monitoring, vaccination and infection instructions, pregnancy planning, access continuity, taper or stop criteria, and a maintenance or next-line strategy.
Quick check
Checking for saved practice…
Lesson
Close the Loop Across Age, Skin, and Life
Children, pregnancy, darker skin, hands and face, atopic comorbidity, infection, sleep, mental health, access, and caregiver technique can change both disease recognition and treatment success.
- Pediatrics
- Pregnancy
- Skin color
- Atopic comorbidity
- Response targets
Use age-specific labels and quantities
Reconcile every topical and systemic exposure
Do not rely on redness alone
Set targets, timing, and escalation
Use pediatric labels and quantities
Age, weight, body surface area, thin skin, growth, caregiver skill, school, sleep, and accidental exposure matter. Demonstrate quantities and keep medicines secured. Unusual infection, failure to thrive, or very early severe disease broadens the differential.
Use narrative reproductive reasoning
Replace old pregnancy letters with product-specific human and animal evidence, maternal disease burden, route, exposure area, timing, alternatives, lactation, and shared goals. Review every topical, systemic, OTC, and natural product.
Recognize inflammation across skin tones
Erythema may appear violaceous, gray, dark brown, or subtle. Texture, warmth, edema, excoriation, lichenification, pigment change, symptoms, and patient comparison help prevent underestimation.
Measure meaningful response
Track extent and intensity with itch, sleep, pain, infection, hand and face function, mood, school or work, treatment time, product amount, and patient goals. Escalate when adequate technique and exposure do not meet targets.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 106 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- AAAAI/ACAAI Atopic Dermatitis Guideline
- DailyMed Cyclosporine Modified Label
- DailyMed Methotrexate Label
- DailyMed Azathioprine Label
- DailyMed Mycophenolate Label
- DailyMed Abrocitinib Label
- DailyMed Upadacitinib Label
- DailyMed Dupilumab Label
- DailyMed Tralokinumab Label
- DailyMed Lebrikizumab Label
- AAP Skin-Directed Atopic Dermatitis Clinical Report
- Fingertip Unit Original Study
- BAD Topical Corticosteroid Patient Guidance
- AAAAI/ACAAI Bleach Bath Guideline Supplement
- DailyMed Nemolizumab Label
- DailyMed Crisaborole Label
- DailyMed Tacrolimus Ointment Label
- DailyMed Pimecrolimus Cream Label
- AAD Atopic Dermatitis Clinical Guideline
- DailyMed Tapinarof Label
- DailyMed Roflumilast Cream Label
- DailyMed Ruxolitinib Cream Label
- FDA Ebglyss Drug Trial Snapshot